[
    [
        {
            "time": "",
            "original_text": "泰格医药2017年净利润3亿元 同比增117%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "净利润",
                    "2017年",
                    "同比增长",
                    "117%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药2017年净利润3亿元 同比增117%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：2017年净利润同比增116.91%（快报）",
            "features": {
                "keywords": [
                    "泰格医药",
                    "净利润",
                    "2017年",
                    "同比增长",
                    "116.91%",
                    "快报"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药：2017年净利润同比增116.91%（快报）",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "[领先大市-A评级]医药行业每周观点：关注业绩超预期及估值增速具备高性价比的投资机会 首推葵花药业和济川药业",
            "features": {
                "keywords": [
                    "医药行业",
                    "业绩超预期",
                    "估值增速",
                    "高性价比",
                    "葵花药业",
                    "济川药业"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[领先大市-A评级]医药行业每周观点：关注业绩超预期及估值增速具备高性价比的投资机会 首推葵花药业和济川药业",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：医药分销板块有望迎来戴维斯双击",
            "features": {
                "keywords": [
                    "医药生物",
                    "分销板块",
                    "戴维斯双击"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：医药分销板块有望迎来戴维斯双击",
                "Correlation": 4,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业研究周报：震荡中拥抱低估值高成长的“安全标的”",
            "features": {
                "keywords": [
                    "医药生物",
                    "低估值",
                    "高成长",
                    "安全标的"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业研究周报：震荡中拥抱低估值高成长的“安全标的”",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]